Analysis of Anti Infection Effect of Piperacillin Tazobactam and Cefoperazone Sulbactam in Elderly Patients with Coronary Heart Disease
Abstract
Objective: to analyze the anti infection effect of piperacillin tazobactam and cefoperazone sulbactam in elderly patients with coronary heart disease. Methods: the experiment was carried out in groups from January 2019 to December 2020. The control group (cefoperazone sulbactam) and the study group (piperacillin tazobactam) were divided into two groups. The experimental patients were 98 elderly patients with coronary heart disease (49 cases in each group). Two groups of comparative indicators: pathogen clearance rate, incidence of adverse reactions. Results: the pathogen clearance rate of the study group was 94.63%, and that of the control group was 81.48%, which was higher than that of the control group (P < 0.05). The incidence of adverse reactions was 3.57% in the study group and 16.33% in the control group, which was lower in the study group than in the control group (P < 0.05). Conclusion: piperacillin tazobactam is better than cefoperazone sulbactam in the treatment of anti infection in elderly patients with coronary heart disease, which can better remove pathogenic bacteria, control various adverse reactions during drug treatment, and ensure the effectiveness and safety of drug use.
References
[2] Feng S. Comparison of clinical efficacy and safety of piperacillin tazobactam and cefoperazone sulbactam in the treatment of infection in elderly patients with coronary heart disease [J]. Anti infective pharmacy2019;16(5):891-893.
[3] Wu H, Pan D, Liu Q, etc. Comparison of clinical efficacy and safety of piperacillin tazobactam and cefoperazone sulbactam in the treatment of infection in elderly patients with coronary heart disease [J]. Anti infective pharmacy 2019;16(10):1760-1762.
[4] Li D. Clinical observation of piperacillin combined with tazobactam in the treatment of senile coronary heart disease with infection [J]. Northern pharmacy 2020;17(2):126-127.
[5] Tao Y. Comparison of piperacillin tazobactam and cefoperazone sulbactam in the treatment of congenital coronary heart disease with infection in children [J]. Journal of clinical rational drug use 2020;13(8):100-101.
[6] Gao Z, Xiao S, Li G. Efficacy and safety of different antimicrobial regimens in the treatment of nosocomial infection in elderly patients with coronary heart disease [J]. Chinese Journal of nosocomial infection 2015;(22):5158-5159,5171.
[7] Du X, Ren L. Observation on the effect of piperacillin tazobactam and cefoperazone sulbactam in the treatment of senile coronary heart disease [J]. Journal of Shandong Medical College 2019;41(5):334.
[8] Gao Y, Zhuang X, Shi L, etc. Comparison of clinical efficacy and safety of piperacillin tazobactam and cefoperazone sulbactam in the treatment of postoperative infection in elderly patients with coronary heart disease[J].Electronic Journal of cardiovascular disease of integrated traditional Chinese and Western Medicine 2019;7(27):29,35.
Copyright (c) 2021 Na Sai
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
